SCHEMBL4879459

SCHEMBL4879459

Cc1cccc(C)c1-n1cc(/C(=N/OCc2ccccn2)c2ccc(F)cc2F)ccc1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.36
LMNA P02545 3/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 2/20 0.33
MAPK14 Q16539 2/20 0.33
SMO Q99835 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP2C9 P11712 1/20 0.33
KCNH2 Q12809 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CTSD P07339 1/20 0.33
GUSB P08236 1/20 0.33
FFAR1 O14842 1/20 0.33
BRD4 O60885 1/20 0.33
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
MAPK8 P45983 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879463 1.00 SYK (0.36) SYKLMNAALDH1A1RAB9AMAPK14
SCHEMBL4878963 0.96 SYK (0.35) SYKLMNAALDH1A1RAB9AMAPK14
SCHEMBL4878969 0.96 SYK (0.35) SYKLMNAALDH1A1RAB9AMAPK14
SCHEMBL4879567 0.91 MAPK14 (0.35) SYKLMNAALDH1A1RAB9AMAPK14
SCHEMBL4879572 0.91 MAPK14 (0.35) SYKLMNAALDH1A1RAB9AMAPK14
SCHEMBL4873528 0.81 CHRNA7 (0.34) RAB9AMAPK14KMT2AL3MBTL1BRD4
SCHEMBL4873533 0.81 CHRNA7 (0.34) RAB9AMAPK14KMT2AL3MBTL1BRD4
SCHEMBL4877732 0.79 DRD4 (0.39) ALDH1A1KMT2AGAA
SCHEMBL4877730 0.79 DRD4 (0.39) ALDH1A1KMT2AGAA
SCHEMBL4879034 0.79 MAPK14 (0.39) MAPK14KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080081825-A1 Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-03 US disclosed
EP-1741702-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081825-A1 Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof MAPK1, NOS1, NOS2 SYK 333/4885LMNA 2177/4885ALDH1A1 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.